Maybe ACH-1625 is on Roches radar. You never know. :)
That would make sense to me (#msg-55252214). Fingers crossed. Either way, I don't expect anything would happen at least until ACHN completes the now commenced Phase 2a trial for ACH-1625. Of course, if Roche licenses an HCV PI from someone other than ACHN, I would obviously view that as a bearish sign for ACHN given that 1625 looks to be the most advanced unpartnered HCV PI.
Market Data 
Markets 
AI
